PRINCETON, N.J., Jan. 2, 2019 /PRNewswire/ -- Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") ...
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
Please provide your email address to receive an email when new articles are posted on . FDA withdrew approval of Makena due to lack of clinical benefit. No medication is currently approved to reduce ...
WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is ...
BAUDETTE, Minn., June 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in ...
On October 5, 2020, the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) proposed withdrawal of approval of Makena (hydroxyprogesterone caproate injection), the ...
The US Food and Drug Administration's (FDA's) Bone, Reproductive and Urologic Drugs Advisory Committee voted by a narrow margin to recommend withdrawing hydroxyprogesterone caproate (17P) injection ...
Nine years after Amag Pharmaceuticals Inc.’s Makena (hydroxyprogesterone caproate injection) received accelerated approval to reduce the risk of preterm birth in certain at-risk pregnancies, the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results